WallStSmart

Boston Scientific Corp (BSX)vsKoninklijke Philips NV ADR (PHG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 13% more annual revenue ($20.07B vs $17.83B). BSX leads profitability with a 14.4% profit margin vs 5.0%. PHG appears more attractively valued with a PEG of 0.36. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

PHG

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 7.3Quality: 5.3
Piotroski: 6/9Altman Z: 1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.0%)

Margin of Safety

+1.0%

Fair Value

$70.62

Current Price

$69.48

$1.14 discount

UndervaluedFair: $70.62Overvalued
PHGSignificantly Overvalued (-340.5%)

Margin of Safety

-340.5%

Fair Value

$7.28

Current Price

$26.25

$18.97 premium

UndervaluedFair: $7.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$103.56B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

PHG4 strengths · Avg: 9.0/10
PEG RatioValuation
0.3610/10

Growing faster than its price suggests

Revenue GrowthGrowth
110.0%10/10

Revenue surging 110.0% year-over-year

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.31B8/10

Generating 1.3B in free cash flow

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
36.0x4/10

Premium valuation, high expectations priced in

PHG4 concerns · Avg: 3.0/10
P/E RatioValuation
26.4x4/10

Moderate valuation

Return on EquityProfitability
7.8%3/10

ROE of 7.8% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

EPS GrowthGrowth
-50.0%2/10

Earnings declined 50.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : PHG

The strongest argument for PHG centers on PEG Ratio, Revenue Growth, Price/Book. Revenue growth of 110.0% demonstrates continued momentum. PEG of 0.36 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : PHG

The primary concerns for PHG are P/E Ratio, Return on Equity, Profit Margin.

Key Dynamics to Monitor

BSX profiles as a growth stock while PHG is a hypergrowth play — different risk/reward profiles.

PHG carries more volatility with a beta of 0.94 — expect wider price swings.

PHG is growing revenue faster at 110.0% — sustainability is the question.

PHG generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 49/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Koninklijke Philips NV ADR

HEALTHCARE · MEDICAL DEVICES · USA

Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.

Want to dig deeper into these stocks?